AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
September 22 2021 - 6:00PM
Business Wire
10-target partnership leverages AbCellera’s
technology to accelerate Everest’s pipeline of novel, innovative
medicines to patients
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX
1952.HK, “Everest”) announced today that they have entered into a
multi-year collaboration and license agreement to discover
therapeutic antibodies for up to 10 targets selected by Everest.
The partnership will help to expand Everest’s portfolio of novel
medicines across multiple indications, with the initial programs
focusing on targets in oncology.
“We are proud to partner with Everest as they build a robust
pipeline of innovative medicines for patients in Asia and beyond,”
said Carl Hansen, Ph.D., CEO and President of AbCellera. “We
believe our full-stack discovery engine, combined with Everest’s
clinical development capabilities, creates synergy and the
opportunity to speed the delivery of therapies to patients around
the world.”
By partnering with AbCellera, Everest will benefit from an
operating system that supports many antibody modalities to unlock
new target classes and open new disease areas to therapeutic
access. The collaboration will leverage the full breadth of
AbCellera’s technology stack, including sourcing fully humanized
antibodies from the Trianni Mouse®, sourcing single domain
antibodies from camelids, and combining any two antibodies to
create native bispecifics using the OrthoMabTM protein engineering
platform.
“This collaboration will allow us to gain access to AbCellera’s
cutting edge, AI-powered antibody discovery platform, which will
greatly accelerate and increase the efficiency of our internal
discovery efforts,” said Jennifer Yang, Ph.D., Chief Scientific
Officer of Everest Medicines.
Under the terms of the agreement, Everest will have the rights
to develop and commercialize antibodies resulting from the
collaboration. AbCellera will receive research payments and is
eligible to receive from Everest downstream clinical and commercial
milestone payments and royalties on net sales of products.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on
developing and commercializing transformative pharmaceutical
products that address critical unmet medical needs for patients in
Asia markets. The management team of Everest Medicines has deep
expertise and an extensive track record of high-quality clinical
development, regulatory affairs, CMC, business development and
operations in Asia and with leading global pharmaceutical
companies. Everest Medicines has built a portfolio of ten
potentially global first-in-class or best-in-class molecules, many
of which are in late stage clinical development. The Company’s
therapeutic areas of interest include oncology, autoimmune
disorders, cardio-renal diseases and infectious diseases. For more
information, please visit its website at
www.everestmedicines.com.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210922005854/en/
Everest Inquiries: Media in US and Europe: Darcie
Robinson, Senior Vice President at Westwicke PR:
darcie.robinson@icrinc.com, +1(203) 919-7905 Media in China: Edmond
Lococo, Managing Director at ICR Asia: edmond.lococo@icrinc.com,
+86 (10) 6583-7510 AbCellera Inquiries: Media: Jessica
Yingling, Ph.D.; media@abcellera.com, +1(236) 521-6774 Business
Development: Neil Berkley; bd@abcellera.com, +1(604) 559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)
729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Sep 2023 to Sep 2024